LMLydia E. Makaroff

Lydia E. Makaroff

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lydia E. Makaroff has a total of 118 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Global prevalence of multiple sclerosis surpasses 3 million: 2024 update of the Multiple Sclerosis International Federation Atlas of MS

    by Rachel King, Ruth Ann Marrie, Ingrid van der Mei, Brenda Banwell, Lydia Makaroff, Nick Rijke, Anne Helme

    Background: The Atlas of MS provides a dataset on multiple sclerosis. This analysis updates the global prevalence (including separate estimates for pediatric multiple sclerosis) and incidence of multiple sclerosis, and examines changes over time using data from 2013, 2020, and 2024. Methods: Countries participating in the 2024 Atlas update confirmed or updated epidemiological data. Global prevalence was estimated using submitted case counts supplemented with pooled subregional rates and, for 2020 and 2024, literature-based imputation. Results: Experts in 133 countries representing 93% of the global population participated. Prevalence data were provided by 118 countries. Global multiple sclerosis prevalence per 100,000 rose from 24.8 (95% confidence interval: 24.73–24.80) in 2013 to 38.1 (95% confidence interval: 38.09–38.17) in 2024 and most regions showed rising prevalence; 3.1 million people now live with multiple sclerosis globally. Higher-income countries reported higher prevalence than lower-income countries. The number of reported pediatric multiple sclerosis cases increased from 7,000 in 2013 to >40,000 in 2024. Incidence data provided by 91 countries estimated that 120,000 new diagnoses occur annually. Conclusion: Global multiple sclerosis prevalence continues to rise. Strengthened and equitable data collection is essential as diagnostic criteria evolve, and these findings provide a benchmark before widespread adoption of the 2024 McDonald criteria.


  • End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer

    by Andrea Necchi, Matthew D. Galsky, Nazli Dizman, David H. Aggen, Neeraj Agarwal, Hikmat Al-Ahmadie, Andrea B. Apolo, Leslie Ballas, Rick Bangs, Peter C. Black, et al.

    PURPOSE: The evolving treatment landscape of muscle-invasive bladder cancer (MIBC) increasingly warrants novel trial design to evaluate perioperative strategies aimed at bladder preservation. To establish standardized outcome measures for evaluating organ preservation strategies in MIBC, the International Bladder Cancer Group (IBCG) and the Global Society of Rare Genitourinary Tumors (GSRGT) assembled an international, multidisciplinary consensus panel. METHODS: The IBCG and GSRGT gathered global bladder cancer experts and patient advocates to establish a framework for risk-adapted bladder-sparing treatment approaches for MIBC. Working groups reviewed the literature and developed draft recommendations, which were discussed at a live meeting in December 2024 in Milan. This was followed by voting by the members using a modified Delphi process. Recommendations achieving ≥75% agreement during the meeting were further refined and presented. RESULTS: Clinical complete response (cCR) definition should encompass the absence of high-grade malignancy on pathology and malignant cells on urine cytology and no evidence of local or metastatic disease on cross-sectional imaging. Although cCR remains immature as a primary or coprimary end point in registrational trials, it could serve as a suitable end point in early-phase studies and risk-adapted investigations. Event-free survival (EFS) remains the preferred primary end point as it could reliably capture the durability of clinically meaningful benefit after omittance of surgical consolidation or chemoradiation. Given the composite nature of EFS, events should be prespecified, evaluated in an intention-to-treat approach, and meticulously collected. Continuous assessment of individual patient preferences should begin at the outset of perioperative therapy discussions, with informed decision making prioritized throughout. CONCLUSION: The consensus definition of cCR and the framework presented in this study can serve as a foundation for thorough testing of risk-adapted bladder-sparing treatment paradigms for MIBC.


  • Open Access

    Redefining Cancer Research Priorities in Low- and Middle-Income Countries in the Post–COVID-19 Global Context: A Modified Delphi Consensus Process

    by Louis Fox, Aida Santaolalla, Jasmine Handford, Richard Sullivan, Julie Torode, Verna Vanderpuye, C.S. Pramesh, Layth Mula-Hussain, Shaymaa AlWaheidi, Lydia E. Makaroff, et al.

    PURPOSE: The post–COVID-19 funding landscape for cancer research globally has become increasingly challenging, particularly in resource-challenged regions (RCRs) lacking strong research ecosystems. We aimed to produce a list of priority areas for cancer research in countries with limited resources, informed by researchers and patients. METHODS: Cancer experts in lower-resource health care systems (as defined by the World Bank as low- and middle-income countries; N = 151) were contacted to participate in a modified consensus-seeking Delphi survey, comprising two rounds. In round 1, participants (n = 69) rated predetermined areas of potential research priority (ARPs) for importance and suggested missing ARPs. In round 2, the same participants (n = 49) rated an integrated list of predetermined and suggested ARPs from round 1, then undertook a forced choice priority ranking exercise. Composite voting scores ( T-scores) were used to rank the ARPs. Importance ratings were summarized descriptively. Findings were discussed with international patient advocacy organization representatives. RESULTS: The top ARP was research into strategies adapting guidelines or treatment strategies in line with available resources (particularly systemic therapy) ( T = 83). Others included cancer registries ( T = 62); prevention ( T = 52); end-of-life care ( T = 53); and value-based and affordable care ( T = 51). The top COVID-19/cancer ARP was strategies to incorporate what has been learned during the pandemic that can be maintained posteriorly ( T = 36). Others included treatment schedule interruption ( T = 24); cost-effective reduction of COVID-19 morbidity/mortality ( T = 19); and pandemic preparedness ( T = 18). CONCLUSION: Areas of strategic priority favored by cancer researchers in RCRs are related to adaptive treatment guidelines; sustainable implementation of cancer registries; prevention strategies; value-based and affordable cancer care; investments in research capacity building; epidemiologic work on local risk factors for cancer; and combatting inequities of prevention and care access.


  • Strategic career building during your PhD: a timeline for maximizing your opportunities

    by Adrian Liston, Lydia E Makaroff

    PhD training can be incredibly versatile, leading to many downstream careers. There is potential to gain training to help you enter any of these careers after graduation. However, it is often only in retrospect that the options and optimal strategies become clear. Here we provide a strategic framework to empower PhD researchers to build and expand their career options in a method compatible with tomorrow's career ecosystem. The strategic framework encourages early career researchers to take a self‐directed approach to establish flexible career goals, diversify exposures and build professional networks. Researchers increase their chances of success by building early markers of multiple career pathways into their PhD program. The framework emphasizes self‐direction, adaptability and resilience, enabling early career researchers to embrace new opportunities and to navigate uncertainties. This structured approach empowers PhD researchers to maximize their opportunities, positioning them for long‐term success in the various career options within and beyond academia.


  • Patient and Carer Experiences with Bladder Cancer: Results from a Global Survey in 45 Countries

    by Lydia E. Makaroff, Alex Filicevas, Shannon Boldon, Patrick Hensley, Peter C. Black, Stephanie Chisolm, Stephanie Demkiw, Mario I. Fernández, Mikio Sugimoto, Bente Thoft Jensen, et al.


  • Open Access

    Diagnosis, treatment and survival from bladder, upper urinary tract, and urethral cancers: real‐world findings from NHS England between 2013 and 2019

    by James W.F. Catto, Olena Mandrik, Lewis A. Quayle, Syed A. Hussain, John McGrath, Joanne Cresswell, Alison J. Birtle, Rob J. Jones, Paramananthan Mariappan, Lydia E. Makaroff, et al.

    Objective: We report NHS England data for patients with bladder cancer (BC), upper tract urothelial cancer (UTUC: renal pelvic and ureteric), and urethral cancers from 2013 to 2019. Materials and Methods: Hospital episode statistics, waiting times, and cancer registrations were extracted from NHS Digital. Results: Registrations included 128 823 individuals with BC, 16 018 with UTUC, and 2533 with urethral cancer. In 2019, 150 816 persons were living with a diagnosis of BC, of whom 113 067 (75.0%) were men, 85 117 (56.5%) were aged >75 years, and 95 553 (91.7%) were Caucasian. Incidence rates were stable (32.7–34.3 for BC, 3.9–4.2 for UTUC and 0.6–0.7 for urethral cancer per 100 000 population). Most patients 52 097 (mean [range] 41.3% [40.7–42.0%]) were referred outside the 2‐week‐wait pathway and 15 340 (mean [range] 12.2% [11.7–12.6%]) presented as emergencies. Surgery, radiotherapy, chemotherapy, or multimodal treatment use varied with disease stage, patient factors and Cancer Alliance. Between 27% and 29% ( n = 6616) of muscle‐invasive BCs did not receive radical treatment. Survival rates reflected stage, grade, location, and tumour histology. Overall survival rates did not improve over time (relative change: 0.97, 95% confidence interval 0.97–0.97) at 2 years in contrast to other cancers. Conclusion: The diagnostic pathway for BC needs improvement. Increases in survival might be delivered through greater use of radical treatment. NHS Digital data offers a population‐wide picture of this disease but does not allow individual outcomes to be matched with disease or patient features and key parameters can be missing or incomplete.


  • Disparities in Access to Novel Systemic Therapies in Patients With Urinary Tract Cancer: Propagating Access, Policies and Resources Uniformly

    by Andrea Necchi, Monika Joshi, Rick Bangs, Lydia Makaroff, Petros Grivas, Ashish M. Kamat, Wassim Kassouf, Daniele Raggi, Laura Marandino, Tracey Krupski, et al.


  • Open Access

    Precision Oncology: a Clinical and Patient Perspective

    by Ulrik N Lassen, Lydia E Makaroff, Albrecht Stenzinger, Antoine Italiano, Gilles Vassal, Jesus Garcia-Foncillas, Bernard Avouac

    Molecular characterization of tumors has shifted cancer treatment strategies away from nonspecific cytotoxic treatment of histology-specific tumors toward targeting of actionable mutations that can... Lay abstract Precision oncology offers individualized treatment of cancer on a per-patient basis, based on the unique DNA fingerprint of a patient’s cancer. New, advanced technologies for DNA seque...


  • Open Access

    Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries

    by Nils Wilking, Anna Bucsics, Lidlija Kandolf Sekulovic, Gisela Kobelt, Andrea Laslop, Lydia Makaroff, Alexander Roediger, Christoph Zielinski

    The Central European Cooperative Oncology Group (CECOG) and ‘ESMO Open—Cancer Horizons’ roundtable discussion brought together stakeholders from several European Union (EU) countries involved in drug development, drug authorisation and reimbursement or otherwise affected by delayed and unequal access to innovative anticancer drugs. The approval process of drugs is well established and access delays can be caused directly or indirectly by national or regional decision-making processes on reimbursement. The two key aspects for those involved in reimbursement decisions are first the level of evidence required to decide and second pricing, which can be challenging for some innovative oncology compounds, especially in Eastern and South-Eastern European countries. Other important factors include: available healthcare budget; the structure and sophistication of healthcare authorities and health technology assessment processes; societal context and political will. From the point of view of the pharmaceutical industry, better alignment between stakeholders in the process and adaptive pathway initiatives is desirable. Key aspects for patients are improved access to clinical trials, preapproval availability and reports on real-world evidence. Restricted access limits oncologists’ daily work in Eastern and South-Eastern EU countries. The roundtable discussion suggested considering the sequencing of regulatory approval and reimbursement decisions together with more flexible contracting as a possible way forward. The panel concluded that early and regular dialogue between all stakeholders including regulators, payers, patient stakeholders and industry is required to improve the situation.


  • IDF Diabetes Atlas estimates of 2014 global health expenditures on diabetes

    by Joao da Rocha Fernandes, Katherine Ogurtsova, Ute Linnenkamp, Leonor Guariguata, Till Seuring, Ping Zhang, David Cavan, Lydia E. Makaroff